| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRNa6 |
| Uniprot No | Q15825 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-239aa |
| 氨基酸序列 | MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGSKGCV GCATEERLFH KLFSHYNQFI RPVENVSDPV TVHFEVAITQ LANVDEVNQI METNLWLRHI WNDYKLRWDP MEYDGIETLR VPADKIWKPD IVLYNNAVGD FQVEGKTKAL LKYNGMITWT PPAIFKSSCP MDITFFPFDH QNCSLKFGSW TYDKAEIDLL IIGSKVDMND FWENSEWEII DASGYKHDIK YNCCEEIYTD ITYSFYIRRL |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRNa6(烟碱型乙酰胆碱受体α6亚基)重组蛋白研究的虚构参考文献示例(实际文献需通过学术数据库查询)：
---
1. **文献名称**: "Functional expression and characterization of recombinant human α6β2 nicotinic acetylcholine receptors"
**作者**: Smith J, et al.
**摘要**: 本研究成功在HEK293细胞中表达并纯化人源α6β2烟碱型乙酰胆碱受体重组蛋白，通过电生理学分析揭示了其配体结合特性及功能调控机制，为靶向α6亚基的药物开发提供依据。
2. **文献名称**: "Structural insights into the α6-containing nicotinic receptors by cryo-EM"
**作者**: Chen L, et al.
**摘要**: 利用冷冻电镜技术解析了重组α6β4烟碱受体蛋白的高分辨率结构，阐明了α6亚基在受体组装和信号转导中的关键作用，揭示了其与神经退行性疾病的潜在关联。
3. **文献名称**: "Role of α6 nicotinic receptors in dopamine release: In vitro reconstitution assays"
**作者**: Garcia R, et al.
**摘要**: 通过重组α6受体蛋白与多巴胺能神经元模型的体外共培养实验，证明α6亚基特异性激活可调节多巴胺释放，提示其在尼古丁成瘾中的病理生理学意义。
4. **文献名称**: "Development of a high-throughput screening platform for α6-targeted compounds using recombinant protein"
**作者**: Wang Y, et al.
**摘要**: 构建基于重组α6烟碱受体蛋白的高通量药物筛选系统，筛选出多个选择性调节剂，为帕金森病和焦虑症的α6靶向治疗策略奠定基础。
---
*注：以上文献为示例性内容，实际研究需查阅具体数据库(如PubMed、Web of Science)并核实原文信息。*
**Background of CHRNA6 Recombinant Protein**
The CHRNA6 gene encodes the α6 subunit of the neuronal nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel critical for synaptic signaling in the nervous system. nAChRs are composed of various α (α2-α10) and β (β2-β4) subunits, with the α6 subunit predominantly expressed in dopaminergic and noradrenergic neurons. CHRNA6-containing receptors play a key role in modulating neurotransmitter release, particularly dopamine, which links them to reward pathways, addiction, and movement regulation. Dysregulation of α6-containing nAChRs has been implicated in neurological disorders, including Parkinson’s disease, nicotine dependence, and psychiatric conditions.
Recombinant CHRNA6 protein is engineered *in vitro* using expression systems like *E. coli* or mammalian cells to produce purified, functional subunits for research. This protein retains the extracellular ligand-binding domain and transmembrane regions, enabling studies on receptor assembly, ligand interactions (e.g., nicotine or acetylcholine), and signaling mechanisms. Researchers utilize CHRNA6 recombinant proteins to investigate its structural biology, screen for therapeutic compounds, or develop antibodies for diagnostic tools.
The development of CHRNA6 recombinant proteins addresses challenges in studying native receptors, which are often low in abundance and embedded in complex neuronal membranes. By providing a controlled, high-purity protein source, it facilitates mechanistic insights into α6-related pathologies and accelerates drug discovery targeting nAChR-associated diseases.
×
